The Antiplatelet Journey Thus Far: Focus On New Oral P2Y12-Inhibitors

REVIEW, January 2012, VOL II ISSUE I, ISSN 2042-4884
10.5083/ejcm.20424884.62 , Cite or Link Using DOI
Creating a Digital Object Identifier Link

A digital object identifier (DOI) can be used to cite and link to electronic documents. A DOI is guaranteed never to change, so you can use it to link permanently to electronic documents.

To find a document using a DOI

  1. Copy the DOI of the document you want to open.
    The correct format for citing a DOI is as follows: doi:10.1016/S0140-6736(08)61345-8
  2. Open the following DOI site in your browser:
  3. Enter the entire DOI citation in the text box provided, and then click Go.
    The document that matches the DOI citation will display in your browser window.

The DOI scheme is administered by the International DOI Foundation. Many of the world's leading publishers have come together to build a DOI-based document linking scheme known as CrossRef.

Morten Würtz, Erik Lerkevang Grove, Steen Dalby Kristensen


Platelets are pivotal in the pathophysiology of acute coronary syndromes; the leading cause of death worldwide. The use of antiplatelet agents in the treatment of acute coronary syndromes has reduced morbidity and mortality substantially. Thus, aspirin has been a cornerstone in the treatment of acute coronary syndromes for years. However, during the last decade the P2Y12 inhibitor clopidogrel has accompanied aspirin to further improve clinical outcomes. P2Y12 inhibitors are antiplatelet agents preventing the binding of adenosine diphosphate to P2Y12 receptors on the platelet surface thus inhibiting platelet aggregation.

Recently, the emergence of two new P2Y12 inhibitors, prasugrel and ticagrelor, has challenged the role of clopidogrel. Similar to clopidogrel, prasugrel is a prodrug that needs hepatic conversion to its active metabolite to provide irreversible P2Y12 inhibition. In contrast, ticagrelor is a direct-acting allosteric P2Y12 antagonist inhibiting the P2Y12 receptor reversibly. Both drugs provide a better protection against cardiovascular outcomes than clopidogrel as evidenced by large clinical trials. This benefit might partly reflect the rapid onset of action and the pronounced antiplatelet effect of these drugs compared to clopidogrel. So far, no direct comparison of prasugrel and ticagrelor has been performed, but ongoing trials will provide data to clarify the clinical role of these drugs.

The present review outlines the key milestones of the history of P2Y12 inhibitors and provides an up-to-date overview and comparison of the clinical applicability of these drugs.